[Effect, on gastric absorption, of a new molecule with mucopoietic activity, 2-)p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine, used in therapy of gastroduodenal diseases].
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D001786:Blood Glucose / Q000096:biosynthesis; D004378:Duodenal Diseases / Q000188:drug therapy*; D005260:Female; D005752:Gastric Mucins / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism; D005759:Gastroenteritis / Q000188:drug therapy*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D010437:Peptic Ulcer / Q000150:complications; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000150:complications; D013450:Sulfones / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D001786:Blood Glucose; D005752:Gastric Mucins; D007093:Imidazoles; D011725:Pyridines; D013450:Sulfones; D005947:Glucose
Effetto sull'assorbimento gastrico di una nuova molecola ad attività mucopoietica, la 2-(p-metilusulfonilfenil)- imidazo (1,2a) piridina, utilizzata nella terapia delle gastroduodenopatie.